CriticalFirst-generation antipsychotics. Butyrophenone derivatives×First-generation antihistamine with anxiolytic activity
Updated · Methodology
Mechanism
Haloperidol prolongs the QTc interval. QTc prolongation, ventricular arrhythmias and sudden death have been reported, and the risk appears to rise with high doses and high plasma concentrations (haloperidol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hydroxyzine is also associated with QT prolongation and torsade de pointes. Its Spanish SmPC states that combining it with haloperidol raises the risk of arrhythmia (hydroxyzine SmPC, AEMPS). CYP3A4 and, to a lesser extent, CYP2D6 take part in haloperidol metabolism. According to limited data, inhibition of these enzymes can raise haloperidol concentrations by 20–40%, and in some cases by up to 100% (haloperidol SmPC, AEMPS). Hydroxyzine inhibits CYP2D6 and at high doses can interact with its substrates (hydroxyzine SmPC, AEMPS). Hydroxyzine has a sedative effect, and haloperidol can increase the central nervous system depression caused by sedatives and hypnotics (hydroxyzine and haloperidol SmPCs, AEMPS).
Symptoms
QTc prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular arrhythmias, including torsade de pointes and ventricular fibrillation, cause palpitations, dizziness and fainting and can end in sudden death (haloperidol and hydroxyzine summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The added sedative effects cause drowsiness and slowed thinking. Haloperidol itself causes drowsiness and lowers blood pressure, including on standing up (haloperidol SmPC, AEMPS), and hydroxyzine causes drowsiness, headache, fatigue and dry mouth (hydroxyzine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names haloperidol (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish haloperidol SmPC also contraindicates haloperidol with all QTc-prolonging drugs and states that its list of examples is not exhaustive (haloperidol SmPC, AEMPS). Hydroxyzine's own SmPC links it to QT prolongation. The US labels of both drugs only advise caution in such combinations (hydroxyzine and haloperidol labels, US Food and Drug Administration, FDA); the Spanish SmPCs are stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Haloperidol is contraindicated in a history of QTc prolongation or ventricular arrhythmia, recent myocardial infarction, decompensated heart failure and uncorrected low potassium (haloperidol SmPC, AEMPS). Before treatment, the haloperidol SmPC recommends a baseline electrocardiogram and correction of low potassium and magnesium, followed by electrolyte monitoring. During treatment, it recommends a lower dose if QTc lengthens and stopping haloperidol if QTc exceeds 500 ms (haloperidol SmPC, AEMPS). If hydroxyzine and haloperidol have nevertheless been taken together, adjust the dose for the added sedation, and stop hydroxyzine if signs of arrhythmia appear (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Haloperidol tablets (haloperidol) prescribing information (2026)– FDA, DailyMed setid afb3ac3e-7459-42d3-b5ca-e0d6d27ced73 (Upsher-Smith Laboratories), version 7, revised 08/2026, Warnings: Cardiovascular Effects
- AEMPS: Ficha técnica: Haloperidol Esteve 2 mg/ml solución oral (nº registro 58355), secciones 4.3, 4.4 y 4.5 (2020)– AEMPS, CIMA, nº registro 58355, revisión 07/2020, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage